TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research ...

Axsome Therapeutics Inc . (NASDAQ:AXSM) stock soared to a 52-week high, reaching a price level of $105.18. The biopharmaceutical company, with a market capitalization of $5 billion, has demonstrated ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) Inc on Tuesday, setting a price target of $210, which is approximately 207.29%... H.C. Wainwright ...

About Axsome Therapeutics, Inc. Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by ...